Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

The study focuses on the Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism, Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers and Comprehensive reporting and insights to support the continued development of HT-KIT.

"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are committed to driving innovative solutions that can transform patient care."

The study aligns with Hoth Therapeutics' mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.